Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.
Source: BioPharma Dive
You may also like
Pluripotent stem cell trial for Huntington’s disease
Jascayd gains UK licence for treatment of pulmonary...
Teva submits FDA application for paediatric Tourette...
Medical-Commercial alignment in rare disease launches:...
Top 10 Best-Selling Drugs 2026
Virtual Cells Go Multiscale to Predict Complex Biology
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.